Having trouble accessing articles? Reset your cache.

Tasigna nilotinib: Phase III data

The open-label, international Phase III ENESTcmr trial in 207 patients showed that a non-significantly greater proportion of patients who switched to Tasigna achieved a confirmed CMR, the primary endpoint,

Read the full 290 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE